Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)

Sai Wen; Nannan Xu; Gang Wang

doi:10.1016/j.heliyon.2022.e12462

Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)

Heliyon. 2022 Dec 19;8(12):e12462. doi: 10.1016/j.heliyon.2022.e12462. eCollection 2022 Dec.

Authors

Sai Wen¹, Nannan Xu¹, Gang Wang¹

Affiliation

¹ Department of Infectious Disease, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high mortality. A 73-year-old woman presented to the hospital with fever after being bitten by ticks and was diagnosed with SFTS. Three days after treatment with high-flow oxygen and supportive therapy, her condition deteriorated to septic shock and multiple organ failure. Ruxolitinib, a JAK1/2 inhibitor, was used for the treatment of cytokine release syndrome, and the patient finally recovered. Ruxolitinib and other host-based immunomodulatory drugs may be potential treatments for fatal SFTS.

Keywords: Cytokine release syndrome; Hyperinflammation; Ruxolitinib; Severe fever with thrombocytopenia syndrome.

Publication types

Case Reports